Selecting Endocrine Therapy for Breast Cancer: What Role Does HER-2/neu Status Play?

Seminars in Oncology

Volumn 33, Issue 6, 2006, Pages 681-687

  Prowell, Tatiana M ^a   Armstrong, Deborah K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; DROLOXIFENE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FADROZOLE; FLUOROURACIL; FULVESTRANT; GOSERELIN; HORMONE RECEPTOR; LETROZOLE; MEGESTROL; MEGESTROL ACETATE; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL HETEROGENEITY; CLINICAL OBSERVATION; CLINICAL STUDY; CLINICAL TRIAL; DATA ANALYSIS; DRUG TARGETING; DRUG TREATMENT FAILURE; EXPERIMENTAL STUDY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HORMONE RESISTANCE; HUMAN; MEDICAL DECISION MAKING; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 37249092437     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.08.016     Document Type: Article

References (47)

1. Pujol P., Daures J.P., Thezenas S., et al. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 83 (1998) 698-705
2. Osborne C.K., Yochmowitz M.G., Knight III W.A., et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46 (1980) 2884-2888
3. Clark G., Osborne C., and McGuire W. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2 (1984) 1102-1109
4. Earp H.S., Dawson T.L., Li X., et al. Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35 (1995) 115-132
5. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
6. Slamon D., Godolphin W., Jones L., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
7. Ross J.S., and Fletcher J.A. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells 16 (1998) 413-428
8. Revillion F., Bonneterre J., and Peyrat J.P. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34 (1998) 791-808
9. Carlson R.W., Brown E., Burstein H.J., et al. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 4 suppl 1 (2006) S1-S26
10. Yaziji H., Goldstein L.C., Barry T.S., et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291 (2004) 1972-1977
11. Benz C.C., Scott G.K., Sarup J.C., et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24 (1992) 85-95
12. Pietras R., Arboleda J., Reese D., et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10 (1995) 2435-2446
13. Konecny G., Pauletti G., Pegram M., et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95 (2003) 142-153
14. Shou J., Massarweh S., Osborne C.K., et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96 (2004) 926-935
15. Liu Y., el-Ashry D., Chen D., et al. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34 (1995) 97-117
16. Kurokawa H., Lenferink A.E., Simpson J.F., et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60 (2000) 5887-5894
17. McShane L.M., Altman D.G., Sauerbrei W., et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23 (2005) 9067-9072
18. Fisher E., Sass R., and Fisher B. Pathologic findings from the National Surgical Adjuvant Project for breast cancers (protocol no. 4). Cancer 53 (1984) 712-723
19. Yamauchi H., Stearns V., and Hayes D.F. When is a tumor marker ready for prime time?. A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19 (2001) 2334-2356
20. Borg A., Baldetrop B., Ferno M., et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Letters 81 (1994) 137-144
21. Sjogren S., Inganas M., Lindgren A., et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16 (1998) 462-469
22. Carlomagno C., Perrone F., Gallo C., et al. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14 (1996) 2702-2708
23. De Placido S., De Laurentiis M., Carlomagno C., et al. Twenty-year results of the Naples GUN randomized trial: Predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 9 (2003) 1039-1046
24. Andrulis I.L., Bull S.B., Blackstein M.E., et al., Toronto Breast Cancer Study Group. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 16 (1998) 1340-1349
25. Knoop A.S., Bentzen S.M., Nielsen M.M., et al. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19 (2001) 3376-3384
26. Berry D.A., Muss H.B., Thor A.D., et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 18 (2000) 3471-3479
27. Paik S., Bryant J., Park C., et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90 (1998) 1361-1370
28. Love R.R., Duc N.B., Allred D.C., et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 20 (2002) 2559-2566
29. Love R.R., Duc N.B., Havighurst T.C., et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21 (2003) 453-457
30. Stal O., Borg A., Ferno M., et al. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 11 (2000) 1545-1550
31. Houston S.J., Plunkett T.A., Barnes D.M., et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79 (1999) 1220-1226
32. Berns E.M.J.J., Foekens J.A., van Staveren I.L., et al. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene 159 (1995) 11-18
33. Wright C., Nicholson S., Angus B., et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65 (1992) 118-121
34. Lipton A., Ali S.M., Leitzel K., et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20 (2002) 1467-1472
35. Leitzel K., Teramoto Y., Konrad K., et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13 (1995) 1129-1135
36. Yamauchi H., O'Neill A., Gelman R., et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15 (1997) 2518-2525
37. Willsher P.C., Beaver J., Pinder S., et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 40 (1996) 251-255
38. Elledge R.M., Green S., Ciocca D., et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study. Clin Cancer Res 4 (1998) 7-12
39. De Laurentiis M., Arpino G., Massarelli E., et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11 (2005) 4741-4748
40. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19 (2001) 3808-3816
41. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23 (2005) 5108-5116
42. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19 (2001) 2596-2606
43. Lipton A., Ali S.M., Leitzel K., et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 21 (2003) 1967-1972
44. Archer S.G., Eliopoulos A., Spandidos D., et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72 (1995) 1259-1266
45. Fehm T., Maimonis P., Katalinic A., et al. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 55 (1998) 33-38
46. Hayes D.F., Yamauchi H., Broadwater G., et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7 (2001) 2703-2711
47. Jukkola A., Bloigu R., Soini Y., et al. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer 37 (2001) 347-354